Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 0.59 |
| ▸ | KIT | P10721 | 10/20 | 0.59 |
| ▸ | KDR | P35968 | 9/20 | 0.59 |
| ▸ | MAPK9 | P45984 | 6/20 | 0.59 |
| ▸ | LCK | P06239 | 6/20 | 0.59 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.59 |
| ▸ | LYN | P07948 | 1/20 | 0.58 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.54 |
| ▸ | CSF1R | P07333 | 1/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.46 |
| ▸ | RAF1 | P04049 | 1/20 | 0.46 |
| ▸ | SGK1 | O00141 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2951672 | 0.89 | MAPK14 (0.64) | MAPK14KITKDRMAPK9LCK | |
| SCHEMBL2946199 | 0.87 | MAPK14 (0.66) | MAPK14KITKDRMAPK9LCK | |
| SCHEMBL5258565 | 0.84 | MAPK14 (0.62) | MAPK14KITKDRMAPK9LCK | |
| SCHEMBL2948130 | 0.83 | MAPK14 (0.61) | MAPK14KITKDRMAPK9LCK | |
| SCHEMBL2949733 | 0.83 | MAPK14 (0.68) | MAPK14KITKDRMAPK9LCK | |
| SCHEMBL2949731 | 0.83 | MAPK14 (0.68) | MAPK14KITKDRMAPK9LCK | |
| SCHEMBL2950521 | 0.83 | MAPK14 (0.68) | MAPK14KITKDRMAPK9LCK | |
| SCHEMBL2949595 | 0.83 | MAPK14 (0.68) | MAPK14KITKDRMAPK9LCK | |
| SCHEMBL3524275 | 0.80 | GPR119 (0.61) | MAPK14KITKDRMAPK9LCK | |
| SCHEMBL398672 | 0.79 | MAPK14 (0.72) | MAPK14KITKDRMAPK9LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2567964-B1 | Monomer compositions for the synthesis of RNA, methods of synthesis, and methods of deprotection | AGILENT TECHNOLOGIES INC (US) | 2015-02-11 | — | — | EP | claimed |
| EP-2567964-A2 | Monomer Compositions for the Synthesis of RNA, Methods of Synthesis, and Methods of Deprotection | Agilent Technologies, Inc. (US) | 2013-03-13 | — | — | EP | claimed |
| US-7759471-B2 | nucleotide monomer used to make protected RNA that has similar stability to the DNA molecule | AGILENT TECHNOLOGIES, INC. (US) | 2010-07-20 | — | — | US | claimed |
| EP-2001896-A2 | MONOMER COMPOSITIONS FOR THE SYNTHESIS OF RNA, METHODS OF SYNTHESIS, AND METHODS OF DEPROTECTION | Agilent Technologies, Inc. (US) | 2008-12-17 | — | — | EP | claimed |
| WO-2007112263-A2 | MONOMER COMPOSITIONS FOR THE SYNTHESIS OF RNA, METHODS OF SYNTHESIS, AND METHODS OF DEPROTECTION | AGILENT TECHNOLOGIES, INC. (US) | 2007-10-04 | — | — | WO | claimed |
| US-20070100138-A1 | Monomer compositions for the synthesis of polynucleotides, methods of synthesis, and methods of deprotection | THE REGENTS OF THE UNIVERSITY OF COLORADO | 2007-05-03 | — | — | US | claimed |
| US-20070100136-A1 | Monomer compositions for the synthesis of RNA, methods of synthesis, and methods of deprotection | AGILENT TECHNOLOGIES, INC. | 2007-05-03 | — | — | US | claimed |
| EP-2567964-B1 | Monomer compositions for the synthesis of RNA, methods of synthesis, and methods of deprotection | AGILENT TECHNOLOGIES INC (US) | 2015-02-11 | — | — | EP | disclosed |
| EP-1856058-B1 | PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2014-09-03 | — | — | EP | disclosed |
| US-8552174-B2 | Solutions, methods, and processes for deprotection of polynucleotides | AGILENT TECHNOLOGIES, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| EP-2567964-A2 | Monomer Compositions for the Synthesis of RNA, Methods of Synthesis, and Methods of Deprotection | Agilent Technologies, Inc. (US) | 2013-03-13 | — | — | EP | disclosed |
| US-8202985-B2 | Monomer compositions for the synthesis of polynucleotides, methods of synthesis, and methods of deprotection | AGILENT TECHNOLOGIES, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-7759337-B2 | Phthalazine compounds and methods of use | AMGEN INC. (US) | 2010-07-20 | — | — | US | disclosed |
| WO-2007112263-A2 | MONOMER COMPOSITIONS FOR THE SYNTHESIS OF RNA, METHODS OF SYNTHESIS, AND METHODS OF DEPROTECTION | AGILENT TECHNOLOGIES, INC. (US) | 2007-10-04 | — | — | WO | disclosed |
| EP-1792909-A1 | Synthesis of polynucleotides | Agilent Technologies, Inc. (US) | 2007-06-06 | — | — | EP | disclosed |
| US-20070100138-A1 | Monomer compositions for the synthesis of polynucleotides, methods of synthesis, and methods of deprotection | THE REGENTS OF THE UNIVERSITY OF COLORADO | 2007-05-03 | — | — | US | disclosed |
| US-20070100137-A1 | Solutions, methods, and processes for deprotection of polynucleotides | THE REGENTS OF THE UNIVERSITY OF COLORADO | 2007-05-03 | — | — | US | disclosed |
| US-20070100136-A1 | Monomer compositions for the synthesis of RNA, methods of synthesis, and methods of deprotection | AGILENT TECHNOLOGIES, INC. | 2007-05-03 | — | — | US | disclosed |
| WO-2006094187-A2 | PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2006-09-08 | — | — | WO | disclosed |
| US-20060199817-A1 | Phthalazine, aza- and diaza-phthalazine compounds and methods of use | AMGEN INC. (US) | 2006-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199817-A1 | Phthalazine, aza- and diaza-phthalazine compounds and methods of use | DAPK2, CDK2, DAPK1 | MAPK14 293/4885KIT 1977/4885KDR 683/4885 |
| US-20070100136-A1 | Monomer compositions for the synthesis of RNA, methods of synthesis, and methods of deprotection | RNGTT, RNMT, NSUN2 | MAPK14 3117/4885KIT 4749/4885KDR 4509/4885 |
| US-20070100138-A1 | Monomer compositions for the synthesis of polynucleotides, methods of synthesis, and methods of deprotection | POLN, NT5C3B, PCNA | MAPK14 2614/4885KIT 4521/4885KDR 3867/4885 |
| US-20070100137-A1 | Solutions, methods, and processes for deprotection of polynucleotides | POLN, POLRMT, POLM | MAPK14 4113/4885KIT 2919/4885KDR 3116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.